Transgene SA (TRGNF) Discusses Progress in Individualized Neoantigen Therapeutic Vaccines and Enlargement into Early-Stage NSCLC Transcript

Operator

Good morning, and welcome to the Transgene digital key opinion chief occasion. At the moment, all attendees are in a listen-only mode and a question-and-answer session will observe the formal presentation.

[Operator Instructions] As a reminder, this name is being recorded, and a replay will likely be made obtainable on the Transgene web site following the conclusion of the occasion.

Earlier than I flip the decision over to Alessandro Riva, Transgene’s Chairman and Chief Government Officer, I would prefer to remind everybody that immediately’s dialogue comprises forward-looking statements, that are topic to a number of dangers and uncertainties. And with that, Alessandro, I will now cross it to you.

Alessandro Riva
CEO & Chairman of the Board

Thanks, and good afternoon and good morning, everybody. When you can transfer to the following slide. So it’s a pleasure to share with you our progress in our Individualized Neoantigen Therapeutic Vaccine that’s our primary program, and we’re specializing in this program because the final 3 years, and we now have made vital progress, not solely with our main asset TG4050, however as you will hear immediately on the brand new program, that is TG4070 in small — in non-small cell lung most cancers.

So it’s a pleasure to have with us immediately a frontrunner within the oncology area that’s Professor Nicolas Girard, who’s Professor of Thoracic Oncology at Curie Institute Paris, and likewise different individuals of Transgene will be part of me as we current the advances in our portfolio.

So if I can go to the following